5-FU therapeutic drug monitoring as a valuable option to reduce toxicity in patients with gastrointestinal cancer.

Fiche publication

Date publication

février 2018

Journal

Oncotarget

Auteurs

Membres identifiés du Cancéropôle Est :
Dr BERTAUT Aurélie , Pr GHIRINGHELLI François , Dr VINCENT Julie , Pr SCHMITT Antonin

Tous les auteurs :
Morawska K, Goirand F, Marceau L, Devaux M, Cueff A, Bertaut A, Vincent J, Bengrine-Lefevre L, Ghiringhelli F, Schmitt A

Lien Pubmed

https://www.ncbi.nlm.nih.gov/pubmed/29545919

Résumé

5-FU is used as the main backbone of chemotherapy regimens for patients with colorectal and other gastrointestinal cancers. Despite development of new strategies that allowed enhancing clinical effectiveness and tolerability of 5-FU, 10-30% of patients treated with 5-FU-based regimens experience severe treatment-related toxicity. In our study, we evaluated the 5-FU exposure-toxicity relationship and investigated the efficacy of PK-guided dosing in increasing tolerability of 5-FU-based chemotherapy.